StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Guggenheim Reiterates Buy Rating on Merck (MRK)
July 16, 2026 6:39 AM
Guggenheim analyst Vamil Divan reiterated a Buy rating and $145.00 price target on Merck (NYSE: MRK).The analyst commented: "Merck partner ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
